Cellectis (NASDAQ:CLLS) Rating Lowered to "Hold" at StockNews.com

Cellectis (NASDAQ:CLLS - Get Free Report) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued to investors on Monday.

Cellectis Stock Up 8.2%

Shares of NASDAQ:CLLS traded up $0.12 during trading hours on Monday, hitting $1.58. The company's stock had a trading volume of 49,716 shares, compared to its average volume of 142,352. Cellectis has a 52 week low of $1.10 and a 52 week high of $3.00. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The company has a market capitalization of $87.82 million, a price-to-earnings ratio of -1.22 and a beta of 3.11. The firm's fifty day moving average price is $1.39 and its 200 day moving average price is $1.58.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). The firm had revenue of $12.03 million during the quarter, compared to analysts' expectations of $12.71 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. As a group, research analysts expect that Cellectis will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Cellectis

A number of hedge funds have recently modified their holdings of the business. Long Focus Capital Management LLC increased its position in Cellectis by 2.2% during the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock worth $5,849,000 after purchasing an additional 100,000 shares during the last quarter. B Group Inc. purchased a new position in Cellectis in the fourth quarter worth approximately $5,547,000. Millennium Management LLC purchased a new position in Cellectis in the fourth quarter worth approximately $962,000. OLD Mission Capital LLC purchased a new stake in shares of Cellectis during the 1st quarter worth approximately $31,000. Finally, Wells Fargo & Company MN lifted its position in shares of Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock worth $44,000 after buying an additional 12,500 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.